The need to individualize therapy in the management of prostate cancer, underpinning the decision to de-escalate treatment or not, still largely depends on the efficacy and duration of hormonal therapy, including androgen receptor and signaling inhibitors. The gene discussed is AR; the disease is Familial prostate cancer.